Indication
To reduce intraocular pressure in patients with chronic open-coat glaucoma or ocular hypertension (the drug is used as a monotherapy, as well as in combination with other drugs).
Medicinal form
Eye drops, solution.
Composition of the substance
active substance: 1 ml of solution contains 5.6 mg of betaxolol hydrochloride, equivalent to betaxolol 5 mg (0.5%);
1 ml of the drug contains 34 drops;
excipients: sodium chloride, disodium edetate, benzalkonium chloride, sodium hydroxide, water for injection.
Pharmacological properties
Pharmacodynamics.
Beetaxolol is a cardioselective beta-blocker without significant membrane-stabilizing properties (local anesthetic effect) and internal sympathomimetic activity. After immersion in the conjunctival sac, betaxolol reduces both elevated and normal intraocular pressure as a result of limiting the production of ocular fluid.
When administered orally, beta-blockers reduce cardiac output in healthy individuals and patients with heart disease. In patients with severe myocardial dysfunction, beta-adrenergic receptor antagonists may inhibit the sympathetic effect required to maintain adequate cardiac function.
Betaxolol does not significantly affect the function of the lungs, while blocking the cardiovascular system with beta-blockers, there is no observation.
The peripheral vasodilating effect of betaxolol was observed in the in vivo study in dogs; The vasodilator effect and blockade of the calcium channels associated with betaxolol have been identified in several studies in vitro , eye vessels and other vessels of rats, turkeys, rabbits, dogs, pigs and bulls. The neuroprotective effect of betaxolol has been demonstrated in vitro and in vivo experiments on the retina of rabbits and cortical cultures of rats.
Pharmacokinetics.
The effect of betaxolol is manifested within 30 minutes with peak at 2 hours. One dose reduces intraocular pressure by 12 hours. After local application of betaxolol, systemic absorption may occur, and unusual reactions may occur, such as after oral administration (see section “Adverse reactions”).
Producer
«UNIMED PHARMA Ltd».
Location of the manufacturer and the address of the place of its operation
Orieskova 11, 821 05 Bratislava, Slovak Republic.